These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22199063)

  • 21. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
    Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS
    J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy.
    Dayal S; Sahu P; Gupta N
    Pediatr Dermatol; 2016 Nov; 33(6):646-651. PubMed ID: 27699846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitiligo, NB-UVB and tacrolimus: our experience in Naples.
    Baldo A; Lodi G; Di Caterino P; Monfrecola G
    G Ital Dermatol Venereol; 2014 Feb; 149(1):123-30. PubMed ID: 24566573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area.
    Shrestha S; Jha AK; Thapa DP; Bhattarai CK; Ghimire A
    Nepal Med Coll J; 2014 Sep; 16(1):1-4. PubMed ID: 25799800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo.
    Bapur Erduran F; Adışen E
    Photodermatol Photoimmunol Photomed; 2016 Sep; 32(5-6):247-253. PubMed ID: 27552312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
    Doss N; Kamoun MR; Dubertret L; Cambazard F; Remitz A; Lahfa M; de Prost Y
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):321-9. PubMed ID: 19563466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
    Hartmann A; Bröcker EB; Hamm H
    J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
    Sisti A; Sisti G; Oranges CM
    An Bras Dermatol; 2016 Apr; 91(2):187-95. PubMed ID: 27192518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
    Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
    J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
    Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
    J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo.
    Shah B; Godse K; Mahajan S; Grandhi S; Shendkar S; Sharma A; Teli C; Pathak R; Parsad D
    Dermatol Ther; 2019 Nov; 32(6):e13109. PubMed ID: 31600833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of microneedling combined with tacrolimus versus either one alone for vitiligo treatment.
    Ebrahim HM; Albalate W
    J Cosmet Dermatol; 2020 Apr; 19(4):855-862. PubMed ID: 32030880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
    Tanghetti EA
    Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study.
    Kawalek AZ; Spencer JM; Phelps RG
    Dermatol Surg; 2004 Feb; 30(2 Pt 1):130-5. PubMed ID: 14756638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimecrolimus cream in repigmentation of vitiligo.
    Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
    Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined microneedling with tacrolimus vs tacrolimus monotherapy for vitiligo treatment.
    Ebrahim HM; Elkot R; Albalate W
    J Dermatolog Treat; 2021 Dec; 32(8):999-1004. PubMed ID: 32041441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
    Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS
    Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.